APA (7th ed.) Citation

JC, S., A, R., SR, F., G, P., L, M., N, T., . . . SN, A. (2025). Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. Expert opinion on biological therapy, 25(10), 1121. https://doi.org/10.1080/14712598.2025.2576506

Chicago Style (17th ed.) Citation

JC, Szepietowski, et al. "Comparative Efficacy and Safety of Biosimilar Bmab 1200 Versus Reference Ustekinumab in Moderate-to-severe Plaque Psoriasis: 52-week Findings from the Phase 3 STELLAR-2 Trial." Expert Opinion on Biological Therapy 25, no. 10 (2025): 1121. https://doi.org/10.1080/14712598.2025.2576506.

MLA (9th ed.) Citation

JC, Szepietowski, et al. "Comparative Efficacy and Safety of Biosimilar Bmab 1200 Versus Reference Ustekinumab in Moderate-to-severe Plaque Psoriasis: 52-week Findings from the Phase 3 STELLAR-2 Trial." Expert Opinion on Biological Therapy, vol. 25, no. 10, 2025, p. 1121, https://doi.org/10.1080/14712598.2025.2576506.